<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.1010354</article-id><article-id pub-id-type="publisher-id">ACM-38212</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20201000000_96681178.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  MicroRNA-155通过P2X7R激活NLRP3炎性小体促进ApoE
  <sup>-/-</sup>小鼠颈动脉粥样硬化斑块的形成
  MicroRNA-155 Activates the NLRP3 Inflammasome by Regulating the P2X7R in Carotid Atherosclerotic Plaques of ApoE
  <sup>-/-</sup> Mice
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>彭</surname><given-names>晴</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>尹</surname><given-names>瑞华</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>朱</surname><given-names>晓岩</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>马</surname><given-names>爱军</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>潘</surname><given-names>旭东</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>青岛大学附属医院神经内科，山东 青岛</addr-line></aff><aff id="aff4"><addr-line>青岛大学附属医院重症医学科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><aff id="aff2"><addr-line>青岛大学，山东 青岛</addr-line></aff><pub-date pub-type="epub"><day>10</day><month>10</month><year>2020</year></pub-date><volume>10</volume><issue>10</issue><fpage>2348</fpage><lpage>2356</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：探索在ApoE
   <sup>−/−</sup>小鼠中，microRNA-155 (miR-155)调控NLRP3炎症小体参与其颈动脉粥样硬化(atherosclerosis, AS)斑块形成的可能机制，为预防和治疗AS提供理论基础。方法：36只6周龄的雄性ApoE
   <sup>−/−</sup>小鼠随机分为6组(每组6只)：blank组、NC组、miR-155 mimic组、miR-155 inhibitor组、miR-155 mimic and NC组、miR-155 mimic and P2X7R(-)组。利用PCR技术检测小鼠颈动脉斑块中miR-155的表达水平，HE染色显示颈动脉内膜，利用western blot技术检测P2X7R、NLRP3炎症小体相关蛋白、IL-1β表达水平。结果：与NC组相比，miR-155 mimic组中miR-155表达、P2X7R、NLRP3炎症小体相关蛋白以及IL-1β表达的升高有显著的统计学意义(P &lt; 0.05)，miR-155 inhibitor组则相反。miR-155 mimic and NC组与miR-155 mimic组中NLRP3炎症小体相关蛋白和IL-1β表达无明显差异，而miR-155 mimic and P2X7R(-)组的蛋白表达均明显减少(P &lt; 0.05)。结论：在ApoE
   <sup>−/−</sup>小鼠中，miR-155可能通过调控P2X7R，激活NLRP3炎症小体，增强炎症反应，从而促进AS斑块的形成和发展。
    Objective: To explore the possible mechanism of microRNA-155 (miR-155) involved in the regulation of NLRP3 inflammasome mediated carotid atherosclerotic plaque formation in ApoE
   <sup>−/−</sup> mice, and to provide theoretical basis for the prevention and treatment of atherosclerosis. Methods: Thirty-six 6-week-old male ApoE
   <sup>−/−</sup> mice were randomly divided into six groups (6 in each group): blank group, NC group, miR-155 mimic group, miR-155 inhibitor group, miR-155 mimic and NC group, miR-155 mimic and P2X7R (-) group. The expression of miR-155 in carotid plaque of mice was detected by PCR. HE staining was used to show the intima of carotid artery. The expressions of P2X7R, NLRP3 inflammasome related proteins and IL-1β in plaque were detected by Western blot. Results: The expression of miR-155, P2X7R, NLRP3 inflammasome related proteins and IL-1β in miR-155 mimic group was significantly higher than that in NC group (P &lt; 0.05). In miR-155 inhibitor group, it was the opposite. There was no significant difference in the expression of NLRP3 inflammasome related proteins and IL-1β between miR-155 mimic and NC group and miR-155 mimic group, but the protein expression of miR-155 mimic and P2X7R (-) group was significantly decreased (P &lt; 0.05). Conclusion: In ApoE
   <sup>−/−</sup> mice, miR-155 may regulate P2X7R to activate NLRP3 inflammasome and enhance inflammatory response, thus promoting the formation and development of atherosclerotic plaque. 
  
 
</p></abstract><kwd-group><kwd>动脉粥样硬化，microRNA-155，P2X7R，NLRP3炎症小体，ApoE<sup>-/-</sup>小鼠, Atherosclerosis</kwd><kwd> MicroRNA-155</kwd><kwd> P2X7R</kwd><kwd> NLRP3 Inflammasome</kwd><kwd> ApoE<sup>-/-</sup> Mice</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探索在ApoE<sup>−</sup><sup>/</sup><sup>−</sup>小鼠中，microRNA-155 (miR-155)调控NLRP3炎症小体参与其颈动脉粥样硬化(atherosclerosis, AS)斑块形成的可能机制，为预防和治疗AS提供理论基础。方法：36只6周龄的雄性ApoE<sup>−</sup><sup>/</sup><sup>−</sup>小鼠随机分为6组(每组6只)：blank组、NC组、miR-155 mimic组、miR-155 inhibitor组、miR-155 mimic and NC组、miR-155 mimic and P2X7R(-)组。利用PCR技术检测小鼠颈动脉斑块中miR-155的表达水平，HE染色显示颈动脉内膜，利用western blot技术检测P2X7R、NLRP3炎症小体相关蛋白、IL-1β表达水平。结果：与NC组相比，miR-155 mimic组中miR-155表达、P2X7R、NLRP3炎症小体相关蛋白以及IL-1β表达的升高有显著的统计学意义(P &lt; 0.05)，miR-155 inhibitor组则相反。miR-155 mimic and NC组与miR-155 mimic组中NLRP3炎症小体相关蛋白和IL-1β表达无明显差异，而miR-155 mimic and P2X7R(-)组的蛋白表达均明显减少(P &lt; 0.05)。结论：在ApoE<sup>−</sup><sup>/</sup><sup>−</sup>小鼠中，miR-155可能通过调控P2X7R，激活NLRP3炎症小体，增强炎症反应，从而促进AS斑块的形成和发展。</p></sec><sec id="s2"><title>关键词</title><p>动脉粥样硬化，microRNA-155，P2X7R，NLRP3炎症小体，ApoE<sup>−</sup><sup>/</sup><sup>−</sup>小鼠</p></sec><sec id="s3"><title>MicroRNA-155 Activates the NLRP3 Inflammasome by Regulating the P2X7R in Carotid Atherosclerotic Plaques of ApoE<sup>−/− </sup>Mice<sup> </sup></title><p>Qing Peng<sup>1</sup>, Ruihua Yin<sup>2</sup>, Xiaoyan Zhu<sup>3</sup>, Aijun Ma<sup>2</sup>, Xudong Pan<sup>2*</sup></p><p><sup>1</sup>Qingdao University, Qingdao Shandong</p><p><sup>2</sup>Department of Neurology, The Affiliated Hospital of the Qingdao University, Qingdao Shandong</p><p><sup>3</sup>DepartmentofCritical Care Medicine, The Affiliated Hospital of the Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/21-1571609x5_hanspub.png" /></p><p>Received: Oct. 1<sup>st</sup>, 2020; accepted: Oct. 16<sup>th</sup>, 2020; published: Oct. 23<sup>rd</sup>, 2020</p><p><img src="//html.hanspub.org/file/21-1571609x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To explore the possible mechanism of microRNA-155 (miR-155) involved in the regulation of NLRP3 inflammasome mediated carotid atherosclerotic plaque formation in ApoE<sup>−/−</sup> mice, and to provide theoretical basis for the prevention and treatment of atherosclerosis. Methods: Thirty-six 6-week-old male ApoE<sup>−/−</sup> mice were randomly divided into six groups (6 in each group): blank group, NC group, miR-155 mimic group, miR-155 inhibitor group, miR-155 mimic and NC group, miR-155 mimic and P2X7R (-) group. The expression of miR-155 in carotid plaque of mice was detected by PCR. HE staining was used to show the intima of carotid artery. The expressions of P2X7R, NLRP3 inflammasome related proteins and IL-1β in plaque were detected by Western blot. Results: The expression of miR-155, P2X7R, NLRP3 inflammasome related proteins and IL-1β in miR-155 mimic group was significantly higher than that in NC group (P &lt; 0.05). In miR-155 inhibitor group, it was the opposite. There was no significant difference in the expression of NLRP3 inflammasome related proteins and IL-1β between miR-155 mimic and NC group and miR-155 mimic group, but the protein expression of miR-155 mimic and P2X7R (-) group was significantly decreased (P &lt; 0.05). Conclusion: In ApoE<sup>−/−</sup> mice, miR-155 may regulate P2X7R to activate NLRP3 inflammasome and enhance inflammatory response, thus promoting the formation and development of atherosclerotic plaque.</p><p>Keywords:Atherosclerosis, MicroRNA-155, P2X7R, NLRP3 Inflammasome, ApoE<sup>-/-</sup> Mice</p><disp-formula id="hanspub.38212-formula7"><graphic xlink:href="//html.hanspub.org/file/21-1571609x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/21-1571609x8_hanspub.png" /> <img src="//html.hanspub.org/file/21-1571609x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>脑卒中是一种严重的急性脑血管疾病，是全球主要的致死原因之一 [<xref ref-type="bibr" rid="hanspub.38212-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.38212-ref2">2</xref>]。在中国，缺血性脑卒中占所有脑卒中的80%以上，它最常见的机制是AS斑块的形成。目前普遍认为，免疫炎症反应是AS形成的主要作用机制之一 [<xref ref-type="bibr" rid="hanspub.38212-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.38212-ref4">4</xref>]。</p><p>NOD样受体热蛋白结构域相关蛋白3 (nucleotide binding oligomerization domain-like receptors protein-3, NLRP3)与凋亡相关微粒蛋白(ASC)、pro-caspase-1共同组成了NLRP3炎症小体，它在动脉粥样硬化形成的炎症过程中占据重要地位 [<xref ref-type="bibr" rid="hanspub.38212-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.38212-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.38212-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.38212-ref8">8</xref>]。近年来的研究发现，在人AS组织中，NLRP3炎症小体相关蛋白的表达明显增高 [<xref ref-type="bibr" rid="hanspub.38212-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.38212-ref10">10</xref>]。而细胞外的嘌呤能离子通道型受体7 (purinergic ligand-gated ion channel 7 receptor, P2X7R)能够快速开放钾离子通道，是激活NLRP3炎症小体的重要因子 [<xref ref-type="bibr" rid="hanspub.38212-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.38212-ref12">12</xref>]。</p><p>MiR-155是炎症相关疾病的多效性调节因子，在多种生理和病理过程中都起到了重要的调控作用 [<xref ref-type="bibr" rid="hanspub.38212-ref13">13</xref>]。我们在过去的研究中发现，miR-155能够调控NLRP3炎症小体，影响动脉粥样硬化斑块的形成和发展 [<xref ref-type="bibr" rid="hanspub.38212-ref14">14</xref>]。因此，我们推断，miR-155可能通过P2X7R途径，间接地激活NLRP3炎症小体，促进IL-1β成熟，激活炎症反应，从而推动AS的进展。本研究在ApoE<sup>−/−</sup>小鼠中建立颈AS模型，研究miR-155对P2X7R以及NLRP3炎症小体相关蛋白表达的影响，及其在颈AS斑块形成中的可能机制，为预防和治疗AS提供理论基础。</p></sec><sec id="s6"><title>2. 材料与方法</title><sec id="s6_1"><title>2.1. 材料</title><p>我们从北京维通利华公司购买ApoE<sup>−/−</sup>小鼠(6周龄，雄性，SPF级)，小鼠体重为23.60 &#177; 1.69 g，饲养于青岛大学附属医院动物实验室，饲养条件为：室温、暗光循环，高脂饮食成分为：15%脂肪、0.25%胆固醇(北京科澳协力饲料有限公司)。内径0.3 mm的硅胶环(山东医疗器械研究所)。慢病毒(汉恒生物)：LV-miR-155 (HH20180330GZH-LV01)，LV-miR-155-RNAi (HH20180330GZH-LV02)；LV-P2X7R-RNAi (HH20180330GZH-LV03)。miR-155 引物(TIANGEN生物)，SYBR qRT-PCR试剂盒(Takara)。抗体：β-actin (Elabscience)，P2X7R、NLRP3、IL-1β (abcam)，ASC (CST)，caspase-1 (Santa Cruz Biotechnology)，兔抗小鼠IgG (Elabscience)。ECL显影液(Millipore公司)。</p></sec><sec id="s6_2"><title>2.2. 动物模型</title><p>在获得青岛大学附属医院医学伦理委员会的批准后，我们开始进行动物实验，我们保证动物实验遵守相关法律和机构准则，并努力减轻动物的痛苦。按照随机原则，将36只小鼠分为6组(每组6只)：blank 组(未转染慢病毒)，negative control (NC)组(转染空载慢病毒)，miR-155 mimic组(转染 LV-miR-155)，miR-155 inhibitor组(转染LV-miR-155-RNAi)，miR-155 mimic and NC组(转染LV-miR-155及空载慢病毒)，miR-155 mimic and P2X7R(-)组(转染LV-miR-155及LV-P2X7R-RNAi)。所有小鼠均喂以高脂饮食(15%脂肪、0.25%胆固醇)。小鼠喂养至8周龄后，给小鼠右颈总动脉插入硅胶环，诱导所有ApoE<sup>−/−</sup>小鼠的颈动脉形成AS斑块，术后48小时从尾静脉注射慢病毒200 μL (2 &#215; 10<sup>8</sup> TU∙mL<sup>−1</sup>)，建立所需实验模型。继续诱导8周后，用1.5%异氟烷将小鼠安乐死，获得小鼠右颈动脉标本，放置于液氮中备用。</p></sec><sec id="s6_3"><title>2.3. 苏木精–伊红(HE)染色</title><p>取小鼠右颈动脉标本，将右颈总动脉用4%多聚甲醛固定，石蜡包埋，切片。用二甲苯I 10 min、二甲苯II 2 min、二甲苯III 1 min，梯度酒精10 min脱蜡，用水冲洗2 min，再用苏木精染色5 min，用水冲洗。然后，用0.3%盐酸乙醇分化2 s，用水冲洗30 s。用0.2%氨水返蓝2 s，用水洗涤3次，每次洗涤2 min，切片在伊红中染色30 s，用水洗涤3次，用梯度酒精、二甲苯I、二甲苯II洗涤3 min，每次洗涤3 min。在玻片上的二甲苯完全风干后，将中性凝胶滴在玻片上，然后用干净的盖玻片密封。在显微镜下观察血管的病理变化。</p></sec><sec id="s6_4"><title>2.4. 实时荧光定量PCR</title><p>从液氮中取实验小鼠右颈总动脉标本，用Trizol提取样本总RNA。每20 mg样本加入1 mL Trizol，将样本捣碎匀浆，室温孵育15 min，4℃、12,000 rpm离心10 min，取上清。加入200 μL氯仿，手动震荡15 s，室温孵育15 min，4℃、12,000 rpm离心10 min，取出最上层水相。加入600 μL异丙醇，混匀，−20℃放置1 h。4℃、12,000 rpm离心15 min，可见RNA沉淀。弃上清，滤纸吸干余液，加入预冷的75%乙醇1 mL，洗涤。4℃、12,000 rpm离心10 min，弃上清，空气干燥15 min，得到RNA沉淀。加入10 μL DEPC水溶解。用分光光度计在260 nm光程下测量RNA浓度。根据逆转录反应试剂盒(112315, Takara)的说明，在聚合酶链反应器上进行逆转录，合成cDNA模板，逆转录反应条件如下：37℃，1 h；85℃，5 min；反应在4℃终止，产生的cDNA在−20℃冰箱储存。根据SYBR qRT-PCR试剂盒(639676, Takara)的使用说明，将cDNA用于实时荧光定量pcr，反应体系为20 μL，包括：10 μL SYBR预混料，2 μL cDNA模板，0.6 μL正向引物和0.6 μL反向引物，6.4 μL ddH<sub>2</sub>O。MiR-155引物(TIANGEN生物)序列为TGC GGT TAA TGC TAA TCG TGA TAG G，内参U6 (SYBR qRT-PCR试剂盒，Takara)序列为：5’-TGA AGG TCG GAG TCA ACG GAT TTG GT-3’ (forward)和5’-AAA TGA GCC CCA GCC TTC ATG-3’ (reverse)。反应条件为：95℃预变性30 s，95℃预变性45个周期30 s，退火20 s，72℃延伸30 s。随后，用2<sup>−ΔΔCt</sup>法分析miR-155的相对表达水平。</p></sec><sec id="s6_5"><title>2.5. Western Blot</title><p>从液氮中取实验小鼠右颈总动脉标本，用RIPA提取样品总蛋白。按照RIPA：PMSF：磷酸酶抑制剂 = 100:1:1的比例配置蛋白裂解液，每20 mg样本中加入200 μL的蛋白裂解液，将样本捣碎匀浆，冰上静置10 min，使样本充分裂解，裂解后的样本在4℃、12,000 rpm离心5 min，取上清液。使用BCA法测蛋白浓度，将样品存放于−20℃冰箱备用。进行分离胶浓度为12%，浓缩胶浓度为5%的SDS-PAGE电泳实验，上样量为20 μL，随后用湿转法将蛋白转移到PVDF膜上，用5%脱脂奶粉将PVDF膜进行封闭，时间为1.5 h。之后将封闭好的PVDF膜分别放入含有β-actin (E-AB-20031, Elabscience, 1:1000)、P2X7R (ab229453, abcam, 1:1000)、NLRP3 (ab210491, abcam, 1:1000)、ASC (67824, CST, 1:1000)、caspase-1 (sc-56036, Santa Cruz Biotechnology, 1:500)、IL-1β (ab9722, abcam, 1:1000)的一抗中孵育过夜，孵育温度为4℃。第二天，回收一抗，用含0.1% tween 20的TBST进行每次10 min的洗膜，共三次。将膜在5%脱脂奶粉配置的兔抗小鼠IgG (E-AB-1003, Elabscience, 1:5000)中室温孵育1.5 h，然后用TBST洗三次。最后，用ECL法进行显色，凝胶成像分析系统用于对PVDF膜的拍照及后续分析。</p></sec><sec id="s6_6"><title>2.6. 统计学分析</title><p>采用prism 5和spss22.0统计软件进行对数据进行统计学分析。用 x &#175; &#177; s 来表示计量资料数据，单因素方差分析用于多组间均数的差异性比较，当P &lt; 0.05时认为差异有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. miR-155对ApoE<sup>−/</sup><sup>−</sup>小鼠颈AS斑块的形成的影响</title><p>使用HE染色观察小鼠颈动脉病理特点，发现，blank及NC组予以颈动脉套管处理后，可见明显内膜增厚，内膜下可见大量炎性细胞、泡沫细胞；与NC相比，miR-155 mimic组可见明显的管腔内斑块，管壁进一步增厚，管腔狭窄严重，几不可见，内膜下泡沫细胞与胆固醇结晶明显增多；而miR-155 inhibitor组程度明显减轻(图1)。</p><p>图1. miR-155对ApoE<sup>−/−</sup>小鼠颈AS斑块的形成的影响(HE染色，400倍)</p></sec><sec id="s7_2"><title>3.2. 各组小鼠miR-155表达</title><p>使用实时荧光定量PCR技术，测定miR-155在每组小鼠颈AS斑块中的表达水平，结果显示blank组和NC组的表达水平无显著差异；与NC组相比，miR-155的水平在miR-155 mimic组中显著升高，而miR-155 inhibitior组则显著降低(P &lt; 0.05) (图2)。</p><p>图2. miR-155在小鼠颈动脉组织中的表达水平(qRT-PCR)</p></sec><sec id="s7_3"><title>3.3. miR-155对ApoE<sup>−/</sup><sup>−</sup>小鼠颈AS斑块中P2X7R、NLRP3炎症小体和IL-1β的表达的影响</title><p>为研究miR-155影响AS斑块形成的机制，我们用western blot方法，检测了P2X7R、NLRP3炎症小体相关蛋白(包括NLRP3、ASC和caspase-1)和IL-1β表达时，发现，blank组和NC组小鼠颈动脉AS斑块中，P2X7R、NLRP3、ASC、caspase-1以及IL-1β表达无明显差异；而上调miR-155，P2X7R、NLRP3、ASC、caspase-1和IL-1β的表达均较NC有明显增多，下调miR-155，上述蛋白较NC有明显的减少(P &lt; 0.05)。图3(a)用Western blot法检测β-actin、P2X7R、NLRP3、ASC、caspase-1、IL-1β的表达。(b)-(f)用直方图展示P2X7R (b)、NLRP3 (c)、ASC (d)、caspase-1 (e)、IL-1β (f)的相对表达(与β-actin水平相对比；*与NC组比较，P &lt; 0.05)。</p><p>图3. miR-155对ApoE<sup>−</sup><sup>/</sup><sup>−</sup>小鼠颈AS斑块中P2X7R、NLRP3炎症小体和IL-1β的表达的影响(western blot)</p></sec><sec id="s7_4"><title>3.4. miR-155通过P2X7R影响NLRP3炎症小体及下游IL-1β的表达</title><p>为了进一步研究miR-155促炎作用的机制，我们分别给miR-155mimic组小鼠注射了空载慢病毒和LV-P2X7R-RNAi，并检测了NLRP3、ASC、caspase-1以及炎症因子IL-1β表达。结果发现，miR-155 mimic组与miR-155 mimic and NC组上述蛋白表达差异不大，而抑制P2X7R的小鼠中，上述蛋白的表达水平明显减少(P &lt; 0.05) (图4)。</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>AS是胆固醇在动脉内膜上堆积，使血管腔变窄甚至堵塞，或是使管壁硬化、破裂，从而引起急性脑血管疾病的发生，AS是缺血性脑卒中的主要病因之一。近几十年来的研究证实，在AS发生发展的整个过程中，炎症反应都发挥了重要作用 [<xref ref-type="bibr" rid="hanspub.38212-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.38212-ref4">4</xref>]。microRNA是一类长度为2l~25个核苷酸的小分子非编码RNA，在转录后抑制基因的表达，是影响AS中信号传递的关键因子。miR-155也是microRNA中的一员。miR-155是一种多效性的调节因子，参与炎症、分化、和氧化应激等多种过程，能够在多种疾病对炎症反应的进程起到重要的调控作用 [<xref ref-type="bibr" rid="hanspub.38212-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.38212-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.38212-ref17">17</xref>]；同时，miR-155也是参与AS调节的重要分子 [<xref ref-type="bibr" rid="hanspub.38212-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.38212-ref14">14</xref>]。本研究探讨了miR-155在ApoE<sup>−/−</sup>小鼠的颈AS形成过程中的作用及其相关机制。</p><p>图4. miR-155通过P2X7R影响NLRP3炎症小体及下游IL-1β的表达(western blot)</p><p>我们用高脂饮食喂养ApoE<sup>−/−</sup>小鼠，并给小鼠进行颈动脉套管，从而构建小鼠颈AS模型。通过qRT-PCR技术验证了不同miR-155表达水平的实验小鼠模型的成功建立。在我们过去的研究中发现，高表达的miR-155能够使小鼠颈AS程度明显加重，管腔内有明显的斑块形成 [<xref ref-type="bibr" rid="hanspub.38212-ref14">14</xref>]。因此，我们认为miR-155能够促进ApoE<sup>−/−</sup>小鼠AS的进展。</p><p>NLRP3是一种模式识别受体(PRR)，属于NOD样受体(NLR)家族的3个亚家族之一，它与ASC、pro-caspase-1共同组成了NLRP3炎症小体。NLRP3炎症小体能够被多种损伤相关分子模式(PAMP)以及病原体相关分子模式(DAMP)所激活，其活化后(pro-caspase-1活化为caspase-1)，能够将IL-1β前体(pro-IL-1β)裂解为成熟体IL-1β，启动炎症反应，促进炎症相关性疾病的进展 [<xref ref-type="bibr" rid="hanspub.38212-ref8">8</xref>]。近年来的研究发现，miR-155能够在系统性硬化、银屑病、移植物抗宿主反应(GVHD)等多种炎症相关性疾病中，对NLRP3炎症小体进行调控，影响疾病的进程 [<xref ref-type="bibr" rid="hanspub.38212-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.38212-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.38212-ref17">17</xref>]。本课题组在过去的研究中发现，在巨噬细胞中，miR-155能将NLRP3炎症小体激活，使其下游的炎症因子成熟，促进AS的进程 [<xref ref-type="bibr" rid="hanspub.38212-ref14">14</xref>]。我们通过western blot实验检测小鼠颈动脉斑块，结果发现miR-155能显著使NLRP3炎症小体相关蛋白及IL-1β表达增加，这与我们过去的体外研究结果一致 [<xref ref-type="bibr" rid="hanspub.38212-ref14">14</xref>]。但miR-155影响NLRP3炎症小体表达的具体作用机理仍不甚明确。</p><p>P2X7R是purinergic受体家族中的一个成员，是一类选择性对的钾离子、钠离子及钙离子可通透的通道，也是炎症反应中重要的调控因子。Piscopiello等 [<xref ref-type="bibr" rid="hanspub.38212-ref18">18</xref>] 发现，P2X7R与人AS斑块形成过程中的炎症反应有关；Lin等 [<xref ref-type="bibr" rid="hanspub.38212-ref19">19</xref>] 的研究发现，在巨噬细胞中，抑制P2X7R能够下调PMA诱导的EMMPRIN和MMP-9的表达，从而影响AS的进展。过去的研究也发现，作为一种ATP配体门控的二次跨膜受体，细胞外的P2X7R能够使钾离子外流，使细胞内的钾离子浓度降低、NLRP3炎症小体激活，介导炎症相关级联反应发生 [<xref ref-type="bibr" rid="hanspub.38212-ref20">20</xref>]，这一过程同样也发生在动脉粥样硬化AS疾病中 [<xref ref-type="bibr" rid="hanspub.38212-ref12">12</xref>]。本次研究利用western blot技术，发现，上调miR-155，能够使小鼠颈AS斑块中的P2X7R的表达水平显著上升；在抑制P2X7R表达的miR-155 mimic小鼠中，NLRP3炎症小体相关蛋白以及其下游的炎症因子(IL-1β)的表达均受到抑制，这也证实了P2X7R在miR-155激活NLRP3炎症小体过程中起到了关键作用，并影响了后续的炎症反应的进展。</p></sec><sec id="s9"><title>5. 结论</title><p>综上所述，本次实验证明，在ApoE<sup>−/−</sup>小鼠中，miR-155能够通过调控P2X7R，使NLRP3炎症小体被激活，增强后续炎症反应，从而促进AS斑块的形成。但是，AS形成机制复杂，miR-155作用机制也多种多样，是否有其他因子参与其中，仍需大量的研究去探索；而且，动物与人体的差异问题也难以解决。尽管如此，miR-155及P2X7R在AS形成过程中的重要作用不可忽视，深入了解miR-155及P2X7R在AS中的作用，将为预防和治疗AS提供理论基础。</p></sec><sec id="s10"><title>基金项目</title><p>国家自然科学基金资助项目(81771259，81971111)，科技部国家重点研发计划(2017YFC1310903)。</p></sec><sec id="s11"><title>致谢</title><p>感谢潘旭东教授国家自然科学基金资助项目(81771259)及科技部国家重点研发计划(2017YFC1310903)对于本研究的支持，感谢马爱军教授国家自然科学基金资助项目(81971111)对本研究的支持及对于实验设计的指导，感谢朱晓岩主任对文章撰写提供的指导，感谢尹瑞华博士提供的实验帮助。</p></sec><sec id="s12"><title>文章引用</title><p>彭 晴,尹瑞华,朱晓岩,马爱军,潘旭东. MicroRNA-155通过P2X7R激活NLRP3炎性小体促进ApoE<sup>-/-</sup>小鼠颈动脉粥样硬化斑块的形成MicroRNA-155 Activates the NLRP3 Inflammasome by Regulating the P2X7R in Carotid Atherosclerotic Plaques of ApoE<sup>-/-</sup> Mice[J]. 临床医学进展, 2020, 10(10): 2348-2356. https://doi.org/10.12677/ACM.2020.1010354</p></sec><sec id="s13"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.38212-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Murray, C.J.L. and Lopez, A.D. (2013) Measuring the Global Burden of Disease. The New England Journal of Medicine, 369, 448-457. &lt;br&gt;https://doi.org/10.1056/NEJMra1201534</mixed-citation></ref><ref id="hanspub.38212-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Simon, I.H., Amanuel, A.A., Kalkidan, H.A., et al. (2017) Global, Regional, and National Disability-Adjusted Life-Years (Dalys) for 333 Diseases and Injuries and Healthy Life Expectancy (Hale) for 195 Countries and Territories, 1990-2016: A Systematic Analysis for the Global Burden of Disease Study 2016. The Lancet, 390, 1260-1344.  
&lt;br&gt;https://doi.org/10.1016/S0140-6736(17)32130-X</mixed-citation></ref><ref id="hanspub.38212-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Hansson, G.K. and Hermansson, A. (2011) The Immune System in Atherosclerosis. Nature Immunology, 12, 204-212.  
&lt;br&gt;https://doi.org/10.1038/ni.2001</mixed-citation></ref><ref id="hanspub.38212-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Libby, P., Lichtman, A.H. and Hansson, G.K. (2013) Immune Effector Mechanisms Implicated in Atherosclerosis: From Mice to Humans. Immunity, 38, 1092-1104. &lt;br&gt;https://doi.org/10.1016/j.immuni.2013.06.009</mixed-citation></ref><ref id="hanspub.38212-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Duewell, P., Kono, H., Rayner, K.J., et al. (2010) NLRP3 Inflammasomes Are Required for Atherogenesis and Activated by Cholesterol Crystals. Nature, 464, 1357-1361. &lt;br&gt;https://doi.org/10.1038/nature08938</mixed-citation></ref><ref id="hanspub.38212-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Baldrighi, M., Mallat, Z. and Li, X. (2017) NLRP3 Inflammasome Pathways in Atherosclerosis. Atherosclerosis, 267, 127-138. &lt;br&gt;https://doi.org/10.1016/j.atherosclerosis.2017.10.027</mixed-citation></ref><ref id="hanspub.38212-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Xiao, H., Lu, M., Lin, T.Y., et al. (2013) Sterol Regulatory Element Binding Protein 2 Activation of NLRP3 Inflammasome in Endothelium Mediates Hemodynamic-Induced Atherosclerosis Susceptibility. Circulation, 128, 632-642.  
&lt;br&gt;https://doi.org/10.1161/CIRCULATIONAHA.113.002714</mixed-citation></ref><ref id="hanspub.38212-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Alena, G., Florian, H. and Eicke, L. (2018) NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis. Circulation Research, 122, 1722-1740. &lt;br&gt;https://doi.org/10.1161/CIRCRESAHA.118.311362</mixed-citation></ref><ref id="hanspub.38212-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Zheng, F., Xing, S.S., Gong, Z.S., Xing, Q.C. (2013) NLRP3 Inflammasomes Show High Expression in Aorta of Patients with Atherosclerosis. Heart Lung &amp; Circulation, 22, 746-750. &lt;br&gt;https://doi.org/10.1016/j.hlc.2013.01.012</mixed-citation></ref><ref id="hanspub.38212-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Varghese, G.P., Folkersen, L., Strawbridge, R.J., et al. (2016) NLRP3 Inflammasome Expression and Activation in Human Atherosclerosis. Journal of the American Heart Association, 5, e003031.  
&lt;br&gt;https://doi.org/10.1161/JAHA.115.003031</mixed-citation></ref><ref id="hanspub.38212-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Virgilio, F.D., Ben, D.D., Sarti, A.C., et al. (2017) The P2X7 Receptor in Infection and Inflammation. Immunity, 47, 15-31. &lt;br&gt;https://doi.org/10.1016/j.immuni.2017.06.020</mixed-citation></ref><ref id="hanspub.38212-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Peng, K., Liu, L., Wei, D., et al. (2015) P2X7R Is Involved in the Progression of Atherosclerosis by Promoting NLRP3 Inflammasome Activation. International Journal of Molecular Medicine, 35, 1179-1188.  
&lt;br&gt;https://doi.org/10.3892/ijmm.2015.2129</mixed-citation></ref><ref id="hanspub.38212-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Faraoni, I., Antonetti, F.R., Cardone, J. and Bonmassar, E. (2009) miR-155 Gene: A Typical Multifunctional microRNA. Biochimica et Biophysica Acta, 1792, 497-505. &lt;br&gt;https://doi.org/10.1016/j.bbadis.2009.02.013</mixed-citation></ref><ref id="hanspub.38212-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Yin, R.H., Zhu, X.Y., Wang, J., Yang, S.N., Ma, A.J., Xiao, Q., Song, J.Y. and Pan, X.D. (2019) MicroRNA-155 Promotes the Ox-LDL-Induced Activation of NLRP3 Inflammasomes via the ERK1/2 Pathway in THP-1 Macrophages and Aggravates Atherosclerosis in ApoE-/- Mice. Annals of Palliative Medicine, 8, 676-689.  
&lt;br&gt;https://doi.org/10.21037/apm.2019.10.11</mixed-citation></ref><ref id="hanspub.38212-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Artlett, C.M., Sassi-Gaha, S., Hope, J.L., Feghali-Bostwick, C.A. and Katsikis, P.D. (2017) Mir-155 Is Overexpressed in Systemic Sclerosis Fibroblasts and Is Required for NLRP3 Inflammasome-Mediated Collagen Synthesis during Fibrosis. Annals of Palliative Medicine, 19, Article No. 144. &lt;br&gt;https://doi.org/10.1186/s13075-017-1331-z</mixed-citation></ref><ref id="hanspub.38212-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Luo, Q., Zeng, J.X., Li, W., Lin, L., Zhou, X., Tian, X., Liu, W.Y., Zhang, L.D. and Zhang, X.B. (2018) Silencing of miR-155 Suppresses Inflammatory Responses in Psoriasis through Inflammasome NLRP3 Regulation. International Journal of Molecular Medicine, 42, 1086-1095. &lt;br&gt;https://doi.org/10.3892/ijmm.2018.3677</mixed-citation></ref><ref id="hanspub.38212-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Chen, S., Smith, B. A. H., Iype, J., et al. (2015) MicroRNA-155-Deficient Dendritic Cells Cause Less Severe GVHD through Reduced Migration and Defective Inflammasome Activation. Blood, 126, 103-112.  
&lt;br&gt;https://doi.org/10.1182/blood-2014-12-617258</mixed-citation></ref><ref id="hanspub.38212-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Piscopiello, M., Sessa, M., Anzalone, N., et al. (2013) P2X7 Receptor Is Expressed in Human Vessels and Might Play a Role in Atherosclerosis. International Journal of Cardiology, 168, 2863-2866.  
&lt;br&gt;https://doi.org/10.1016/j.ijcard.2013.03.084</mixed-citation></ref><ref id="hanspub.38212-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Lin, L., Huang, S.J., Zhu, Z.Y., Han, J.B., Wang, Z.X., Huang, W.J. and Huang, Z.Q. (2018) P2X7 Receptor Regulates EMMPRIN and MMP-9 Expression through AMPK/MAPK Signaling in PMA-Induced Macrophages. Molecular Medicine Reports, 18, 3027-3033. &lt;br&gt;https://doi.org/10.3892/mmr.2018.9282</mixed-citation></ref><ref id="hanspub.38212-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Garcia-Martinez, I., Shaker, M.E. and Mehal, W.Z. (2015) Therapeutic Opportunities in Damage-Associated Molecular Pattern-Driven Metabolic Diseases. Antioxidants &amp; Redox Signaling, 23, 1305-1315.  
&lt;br&gt;https://doi.org/10.1089/ars.2015.6383</mixed-citation></ref></ref-list></back></article>